Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ).

Cawlfield A, Genito CJ, Beck Z, Bergmann-Leitner ES, Bitzer AA, Soto K, Zou X, Hadiwidjojo SH, Gerbasi RV, Mullins AB, Noe A, Waters NC, Alving CR, Matyas GR, Dutta S.

Vaccine. 2019 Jun 27;37(29):3793-3803. doi: 10.1016/j.vaccine.2019.05.059. Epub 2019 May 28.

2.

Polymorphisms in Plasmodium falciparum Kelch 13 and P. vivax Kelch 12 Genes in Parasites Collected from Three South Pacific Countries Prior to Extensive Exposure to Artemisinin Combination Therapies.

Gresty K, Anderson K, Pasay C, Waters NC, Cheng Q.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00536-19. doi: 10.1128/AAC.00536-19. Print 2019 Jul.

PMID:
31036683
3.

Editorial: Malaria in the Korean peninsula: Risk factors, latent infections, and the possible role of tafenoquine, a new antimalarial weapon.

Fukuda MM, Wojnarski M, Martin N, Zottig V, Waters NC.

MSMR. 2018 Nov;25(11):2-3. No abstract available.

4.

Erratum: Author Correction: Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity.

Coccia M, Collignon C, Hervé C, Chalon A, Welsby I, Detienne S, van Helden MJ, Dutta S, Genito CJ, Waters NC, Van Deun K, Smilde AK, van den Berg RA, Franco D, Bourguignon P, Morel S, Garçon N, Lambrecht BN, Goriely S, van der Most R, Didierlaurent AM.

NPJ Vaccines. 2018 Mar 21;3:13. doi: 10.1038/s41541-018-0047-7. eCollection 2018.

5.

Major Threat to Malaria Control Programs by Plasmodium falciparum Lacking Histidine-Rich Protein 2, Eritrea.

Berhane A, Anderson K, Mihreteab S, Gresty K, Rogier E, Mohamed S, Hagos F, Embaye G, Chinorumba A, Zehaie A, Dowd S, Waters NC, Gatton ML, Udhayakumar V, Cheng Q, Cunningham J.

Emerg Infect Dis. 2018 Mar;24(3):462-470. doi: 10.3201/eid2403.171723.

6.

Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity.

Coccia M, Collignon C, Hervé C, Chalon A, Welsby I, Detienne S, van Helden MJ, Dutta S, Genito CJ, Waters NC, Deun KV, Smilde AK, Berg RAVD, Franco D, Bourguignon P, Morel S, Garçon N, Lambrecht BN, Goriely S, Most RV, Didierlaurent AM.

NPJ Vaccines. 2017 Sep 8;2:25. doi: 10.1038/s41541-017-0027-3. eCollection 2017. Erratum in: NPJ Vaccines. 2018 Mar 21;3:13.

7.

Inhibiting the Plasmodium eIF2α Kinase PK4 Prevents Artemisinin-Induced Latency.

Zhang M, Gallego-Delgado J, Fernandez-Arias C, Waters NC, Rodriguez A, Tsuji M, Wek RC, Nussenzweig V, Sullivan WJ Jr.

Cell Host Microbe. 2017 Dec 13;22(6):766-776.e4. doi: 10.1016/j.chom.2017.11.005.

8.

Delayed fractional dose regimen of the RTS,S/AS01 malaria vaccine candidate enhances an IgG4 response that inhibits serum opsonophagocytosis.

Chaudhury S, Regules JA, Darko CA, Dutta S, Wallqvist A, Waters NC, Jongert E, Lemiale F, Bergmann-Leitner ES.

Sci Rep. 2017 Aug 11;7(1):7998. doi: 10.1038/s41598-017-08526-5.

9.

Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.

Genito CJ, Beck Z, Phares TW, Kalle F, Limbach KJ, Stefaniak ME, Patterson NB, Bergmann-Leitner ES, Waters NC, Matyas GR, Alving CR, Dutta S.

Vaccine. 2017 Jul 5;35(31):3865-3874. doi: 10.1016/j.vaccine.2017.05.070. Epub 2017 Jun 7.

10.

Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomes.

Phares TW, May AD, Genito CJ, Hoyt NA, Khan FA, Porter MD, DeBot M, Waters NC, Saudan P, Dutta S.

Malar J. 2017 Mar 13;16(1):115. doi: 10.1186/s12936-017-1766-3.

11.

Rationale for Further Development of a Vaccine Based on the Circumsporozoite Protein of Plasmodium vivax.

Yadava A, Waters NC.

PLoS Negl Trop Dis. 2017 Jan 12;11(1):e0005164. doi: 10.1371/journal.pntd.0005164. eCollection 2017 Jan. No abstract available.

12.

The Utility of Malaria Rapid Diagnostic Tests as a Tool in Enhanced Surveillance for Malaria Elimination in Vanuatu.

Donald W, Pasay C, Guintran JO, Iata H, Anderson K, Nausien J, Gresty KJ, Waters NC, Vestergaard LS, Taleo G, Cheng Q.

PLoS One. 2016 Nov 30;11(11):e0167136. doi: 10.1371/journal.pone.0167136. eCollection 2016.

13.

Variable Mortality From the 1918-1919 Influenza Pandemic During Military Training.

Shanks GD, Burroughs S, Sohn JD, Waters NC, Smith VF, Waller M, Brundage JF.

Mil Med. 2016 Aug;181(8):878-82. doi: 10.7205/MILMED-D-15-00124.

PMID:
27483527
14.

Correlation between Cyclin Dependent Kinases and Artemisinin-Induced Dormancy in Plasmodium falciparum In Vitro.

Gray KA, Gresty KJ, Chen N, Zhang V, Gutteridge CE, Peatey CL, Chavchich M, Waters NC, Cheng Q.

PLoS One. 2016 Jun 21;11(6):e0157906. doi: 10.1371/journal.pone.0157906. eCollection 2016.

15.

Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine.

Farooq F, Beck K, Paolino KM, Phillips R, Waters NC, Regules JA, Bergmann-Leitner ES.

Sci Rep. 2016 Jun 21;6:27944. doi: 10.1038/srep27944.

16.

Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study.

Regules JA, Cicatelli SB, Bennett JW, Paolino KM, Twomey PS, Moon JE, Kathcart AK, Hauns KD, Komisar JL, Qabar AN, Davidson SA, Dutta S, Griffith ME, Magee CD, Wojnarski M, Livezey JR, Kress AT, Waterman PE, Jongert E, Wille-Reece U, Volkmuth W, Emerling D, Robinson WH, Lievens M, Morelle D, Lee CK, Yassin-Rajkumar B, Weltzin R, Cohen J, Paris RM, Waters NC, Birkett AJ, Kaslow DC, Ballou WR, Ockenhouse CF, Vekemans J.

J Infect Dis. 2016 Sep 1;214(5):762-71. doi: 10.1093/infdis/jiw237. Epub 2016 Jun 13.

PMID:
27296848
17.

The biological function of antibodies induced by the RTS,S/AS01 malaria vaccine candidate is determined by their fine specificity.

Chaudhury S, Ockenhouse CF, Regules JA, Dutta S, Wallqvist A, Jongert E, Waters NC, Lemiale F, Bergmann-Leitner E.

Malar J. 2016 May 31;15:301. doi: 10.1186/s12936-016-1348-9.

18.

Enhanced risk of illness during the 1918 influenza pandemic after previous influenza-like illnesses in three military populations.

Shanks GD, Burroughs SA, Sohn JD, Waters NC, Smith VF, Waller M, Brundage JF.

Epidemiol Infect. 2016 Jul;144(10):2043-8. doi: 10.1017/S0950268816000479. Epub 2016 Mar 9.

PMID:
26957052
19.

Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01.

Payne RO, Milne KH, Elias SC, Edwards NJ, Douglas AD, Brown RE, Silk SE, Biswas S, Miura K, Roberts R, Rampling TW, Venkatraman N, Hodgson SH, Labbé GM, Halstead FD, Poulton ID, Nugent FL, de Graaf H, Sukhtankar P, Williams NC, Ockenhouse CF, Kathcart AK, Qabar AN, Waters NC, Soisson LA, Birkett AJ, Cooke GS, Faust SN, Woods C, Ivinson K, McCarthy JS, Diggs CL, Vekemans J, Long CA, Hill AV, Lawrie AM, Dutta S, Draper SJ.

J Infect Dis. 2016 Jun 1;213(11):1743-51. doi: 10.1093/infdis/jiw039. Epub 2016 Feb 4. Erratum in: J Infect Dis. 2016 Sep 15;214(6):978.

20.

Mitochondrial Membrane Potential in a Small Subset of Artemisinin-Induced Dormant Plasmodium falciparum Parasites In Vitro.

Peatey CL, Chavchich M, Chen N, Gresty KJ, Gray KA, Gatton ML, Waters NC, Cheng Q.

J Infect Dis. 2015 Aug 1;212(3):426-34. doi: 10.1093/infdis/jiv048. Epub 2015 Jan 29.

PMID:
25635122
21.

Genetic mutations in pfcrt and pfmdr1 at the time of artemisinin combination therapy introduction in South Pacific islands of Vanuatu and Solomon Islands.

Gresty KJ, Gray KA, Bobogare A, Taleo G, Hii J, Wini L, Cheng Q, Waters NC.

Malar J. 2014 Oct 15;13:406. doi: 10.1186/1475-2875-13-406.

22.
23.

Fatty acid synthesis and pyruvate metabolism pathways remain active in dihydroartemisinin-induced dormant ring stages of Plasmodium falciparum.

Chen N, LaCrue AN, Teuscher F, Waters NC, Gatton ML, Kyle DE, Cheng Q.

Antimicrob Agents Chemother. 2014 Aug;58(8):4773-81. doi: 10.1128/AAC.02647-14. Epub 2014 Jun 9.

24.

The role of Pfmdr1 and Pfcrt in changing chloroquine, amodiaquine, mefloquine and lumefantrine susceptibility in western-Kenya P. falciparum samples during 2008-2011.

Eyase FL, Akala HM, Ingasia L, Cheruiyot A, Omondi A, Okudo C, Juma D, Yeda R, Andagalu B, Wanja E, Kamau E, Schnabel D, Bulimo W, Waters NC, Walsh DS, Johnson JD.

PLoS One. 2013 May 13;8(5):e64299. doi: 10.1371/journal.pone.0064299. Print 2013.

25.

Antiplasmodial activity of compounds from the surface exudates of Senecio roseiflorus.

Kerubo LO, Midiwo JO, Derese S, Langat MK, Akala HM, Waters NC, Peter M, Heydenreich M.

Nat Prod Commun. 2013 Feb;8(2):175-6.

PMID:
23513721
26.

Cyclization of the antimicrobial peptide gomesin with native chemical ligation: influences on stability and bioactivity.

Chan LY, Zhang VM, Huang YH, Waters NC, Bansal PS, Craik DJ, Daly NL.

Chembiochem. 2013 Mar 18;14(5):617-24. doi: 10.1002/cbic.201300034. Epub 2013 Feb 20.

PMID:
23426877
27.

Recent highlights in anti-protozoan drug development and resistance research.

Buckner FS, Waters NC, Avery VM.

Int J Parasitol Drugs Drug Resist. 2012 Jun 12;2:230-5. doi: 10.1016/j.ijpddr.2012.05.002. eCollection 2012 Dec.

28.

The antiplasmodial and radical scavenging activities of flavonoids of Erythrina burttii.

Yenesew A, Akala HM, Twinomuhwezi H, Chepkirui C, Irungu BN, Eyase FL, Kamatenesi-Mugisha M, Kiremire BT, Johnson JD, Waters NC.

Acta Trop. 2012 Aug;123(2):123-7. doi: 10.1016/j.actatropica.2012.04.011. Epub 2012 Apr 30.

PMID:
22575309
29.

Targeting protein kinases in the malaria parasite: update of an antimalarial drug target.

Zhang VM, Chavchich M, Waters NC.

Curr Top Med Chem. 2012;12(5):456-72. Review.

PMID:
22242850
30.

Antimalarial drug sensitivity profile of western Kenya Plasmodium falciparum field isolates determined by a SYBR Green I in vitro assay and molecular analysis.

Akala HM, Eyase FL, Cheruiyot AC, Omondi AA, Ogutu BR, Waters NC, Johnson JD, Polhemus ME, Schnabel DC, Walsh DS.

Am J Trop Med Hyg. 2011 Jul;85(1):34-41. doi: 10.4269/ajtmh.2011.10-0674.

31.

Increased prevalence of the pfdhfr/phdhps quintuple mutant and rapid emergence of pfdhps resistance mutations at codons 581 and 613 in Kisumu, Kenya.

Spalding MD, Eyase FL, Akala HM, Bedno SA, Prigge ST, Coldren RL, Moss WJ, Waters NC.

Malar J. 2010 Nov 24;9:338. doi: 10.1186/1475-2875-9-338.

32.

Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases.

Caridha D, Kathcart AK, Jirage D, Waters NC.

Bioorg Med Chem Lett. 2010 Jul 1;20(13):3863-7. doi: 10.1016/j.bmcl.2010.05.039. Epub 2010 May 21.

PMID:
20627564
33.

Promising drug targets in the identification of novel antimalarials.

Waters NC.

Infect Disord Drug Targets. 2010 Jun;10(3):132-3. No abstract available.

PMID:
20462397
34.

Exploring novel targets for antimalarial drug discovery: plasmodial protein kinases.

Jirage D, Keenan SM, Waters NC.

Infect Disord Drug Targets. 2010 Jun;10(3):134-46. Review.

PMID:
20334624
35.

Leveraging cell cycle analysis in anticancer drug discovery to identify novel plasmodial drug targets.

Kozlov S, Waters NC, Chavchich M.

Infect Disord Drug Targets. 2010 Jun;10(3):165-90. Review.

PMID:
20334621
36.

The malarial CDK Pfmrk and its effector PfMAT1 phosphorylate DNA replication proteins and co-localize in the nucleus.

Jirage D, Chen Y, Caridha D, O'Neil MT, Eyase F, Witola WH, Mamoun CB, Waters NC.

Mol Biochem Parasitol. 2010 Jul;172(1):9-18. doi: 10.1016/j.molbiopara.2010.03.009. Epub 2010 Mar 21.

PMID:
20332005
37.

Assessment of malaria in vitro drug combination screening and mixed-strain infections using the malaria Sybr green I-based fluorescence assay.

Co EM, Dennull RA, Reinbold DD, Waters NC, Johnson JD.

Antimicrob Agents Chemother. 2009 Jun;53(6):2557-63. doi: 10.1128/AAC.01370-08. Epub 2009 Apr 6.

38.

Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones.

Geyer JA, Keenan SM, Woodard CL, Thompson PA, Gerena L, Nichols DA, Gutteridge CE, Waters NC.

Bioorg Med Chem Lett. 2009 Apr 1;19(7):1982-5. doi: 10.1016/j.bmcl.2009.02.042. Epub 2009 Feb 13.

PMID:
19250824
39.

Targeting the fatty acid biosynthesis enzyme, beta-ketoacyl-acyl carrier protein synthase III (PfKASIII), in the identification of novel antimalarial agents.

Lee PJ, Bhonsle JB, Gaona HW, Huddler DP, Heady TN, Kreishman-Deitrick M, Bhattacharjee A, McCalmont WF, Gerena L, Lopez-Sanchez M, Roncal NE, Hudson TH, Johnson JD, Prigge ST, Waters NC.

J Med Chem. 2009 Feb 26;52(4):952-63. doi: 10.1021/jm8008103.

40.

Synthesis and biological evaluation of novel sulfonyl-naphthalene-1,4-diols as FabH inhibitors.

Alhamadsheh MM, Waters NC, Sachdeva S, Lee P, Reynolds KA.

Bioorg Med Chem Lett. 2008 Dec 15;18(24):6402-5. doi: 10.1016/j.bmcl.2008.10.097. Epub 2008 Oct 25.

PMID:
18996691
41.

Protein kinases of malaria parasites: an update.

Doerig C, Billker O, Haystead T, Sharma P, Tobin AB, Waters NC.

Trends Parasitol. 2008 Dec;24(12):570-7. doi: 10.1016/j.pt.2008.08.007. Epub 2008 Oct 8. Review.

PMID:
18845480
42.

Recent advances in malaria drug discovery.

Lanteri CA, Johnson JD, Waters NC.

Recent Pat Antiinfect Drug Discov. 2007 Jun;2(2):95-114. Review.

PMID:
18221166
43.

Evaluation of broad spectrum protein kinase inhibitors to probe the architecture of the malarial cyclin dependent protein kinase Pfmrk.

Woodard CL, Keenan SM, Gerena L, Welsh WJ, Geyer JA, Waters NC.

Bioorg Med Chem Lett. 2007 Sep 1;17(17):4961-6. Epub 2007 Jun 12.

PMID:
17588749
44.

Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.

Johnson JD, Dennull RA, Gerena L, Lopez-Sanchez M, Roncal NE, Waters NC.

Antimicrob Agents Chemother. 2007 Jun;51(6):1926-33. Epub 2007 Mar 19.

45.

Synthesis and biological evaluation of thiazolidine-2-one 1,1-dioxide as inhibitors of Escherichia coli beta-ketoacyl-ACP-synthase III (FabH).

Alhamadsheh MM, Waters NC, Huddler DP, Kreishman-Deitrick M, Florova G, Reynolds KA.

Bioorg Med Chem Lett. 2007 Feb 15;17(4):879-83. Epub 2006 Dec 1.

PMID:
17189694
46.

Vangueria infausta root bark: in vivo and in vitro antiplasmodial activity.

Abosl AO, Mbukwa E, Majinda RR, Raserok BH, Yenesew A, Midiwo JO, Akala H, Liyala P, Waters NC.

Br J Biomed Sci. 2006;63(3):129-33.

PMID:
17058713
47.

Identification of an effector protein and gain-of-function mutants that activate Pfmrk, a malarial cyclin-dependent protein kinase.

Chen Y, Jirage D, Caridha D, Kathcart AK, Cortes EA, Dennull RA, Geyer JA, Prigge ST, Waters NC.

Mol Biochem Parasitol. 2006 Sep;149(1):48-57. Epub 2006 May 15.

PMID:
16737745
48.

Antiplasmodial flavonoids from Erythrina sacleuxii.

Andayi AW, Yenesew A, Derese S, Midiwo JO, Gitu PM, Jondiko OJ, Akala H, Liyala P, Wangui J, Waters NC, Heydenreich M, Peter MG.

Planta Med. 2006 Feb;72(2):187-9.

PMID:
16491458
49.

Targeting malaria with specific CDK inhibitors.

Geyer JA, Prigge ST, Waters NC.

Biochim Biophys Acta. 2005 Dec 30;1754(1-2):160-70. Epub 2005 Sep 9. Review.

PMID:
16185941
50.

Rational inhibitor design and iterative screening in the identification of selective plasmodial cyclin dependent kinase inhibitors.

Keenan SM, Geyer JA, Welsh WJ, Prigge ST, Waters NC.

Comb Chem High Throughput Screen. 2005 Feb;8(1):27-38. Review.

PMID:
15720195

Supplemental Content

Loading ...
Support Center